RATIONALE: Much evidence indicates that individuals use tobacco primarily to experience the psychopharmacological properties of nicotine. Varenicline, a partial α4β2 nicotinic acetylcholine receptor (nAChR) agonist, is effective in reducing nicotine craving and relapse in smokers, suggesting that α4β2 nAChRs may play a key role in nicotine dependence. In rats, the effect of varenicline on nicotine intake has only been studied with limited access to the drug, a model of the positive reinforcing effect of nicotine. Varenicline has not been tested on the increase in motivation to take nicotine in nicotine-dependent rats. OBJECTIVES: The present study evaluated the effects of varenicline on nicotine intake in rats with extended access to nicotine self-administration (23 h/day), a condition leading to the development of nicotine dependence. We hypothesized that varenicline's effects on nicotine self-administration would be greater in rats with extended than limited access to the drug and after forced abstinence rather than during baseline self-administration. RESULTS: Varenicline dose-dependently decreased nicotine self-administration in rats with limited (1 h/day) and extended (23 h/day) access. Despite an increased sensitivity to the motivational effects of abstinence on nicotine intake compared with limited-access rats, varenicline was equally effective in decreasing nicotine intake in dependent rats with extended access to nicotine. CONCLUSION: These results suggest that α4β2 nAChRs are critical in mediating the positive reinforcing effects of nicotine but may not be a key element underlying the negative reinforcement process responsible for the increased nicotine intake after abstinence in dependent subjects.
RATIONALE: Much evidence indicates that individuals use tobacco primarily to experience the psychopharmacological properties of nicotine. Varenicline, a partial α4β2 nicotinic acetylcholine receptor (nAChR) agonist, is effective in reducing nicotine craving and relapse in smokers, suggesting that α4β2 nAChRs may play a key role in nicotine dependence. In rats, the effect of varenicline on nicotine intake has only been studied with limited access to the drug, a model of the positive reinforcing effect of nicotine. Varenicline has not been tested on the increase in motivation to take nicotine in nicotine-dependent rats. OBJECTIVES: The present study evaluated the effects of varenicline on nicotine intake in rats with extended access to nicotine self-administration (23 h/day), a condition leading to the development of nicotine dependence. We hypothesized that varenicline's effects on nicotine self-administration would be greater in rats with extended than limited access to the drug and after forced abstinence rather than during baseline self-administration. RESULTS:Varenicline dose-dependently decreased nicotine self-administration in rats with limited (1 h/day) and extended (23 h/day) access. Despite an increased sensitivity to the motivational effects of abstinence on nicotine intake compared with limited-access rats, varenicline was equally effective in decreasing nicotine intake in dependent rats with extended access to nicotine. CONCLUSION: These results suggest that α4β2 nAChRs are critical in mediating the positive reinforcing effects of nicotine but may not be a key element underlying the negative reinforcement process responsible for the increased nicotine intake after abstinence in dependent subjects.
Authors: L M Marubio; A M Gardier; S Durier; D David; R Klink; M M Arroyo-Jimenez; J M McIntosh; F Rossi; N Champtiaux; M Zoli; J-P Changeux Journal: Eur J Neurosci Date: 2003-04 Impact factor: 3.386
Authors: A J Grottick; G Trube; W A Corrigall; J Huwyler; P Malherbe; R Wyler; G A Higgins Journal: J Pharmacol Exp Ther Date: 2000-09 Impact factor: 4.030
Authors: Amira Y Moreno; Marc R Azar; Noelle A Warren; Tobin J Dickerson; George F Koob; Kim D Janda Journal: Mol Pharm Date: 2010-04-05 Impact factor: 4.939
Authors: Thomas J Hopkins; Laura E Rupprecht; Matthew R Hayes; Julie A Blendy; Heath D Schmidt Journal: Neuropsychopharmacology Date: 2012-06-06 Impact factor: 7.853
Authors: Bernard Le Foll; Munmun Chakraborty-Chatterjee; Shaul Lev-Ran; Chanel Barnes; Abhiram Pushparaj; Islam Gamaleddin; Yijin Yan; Maram Khaled; Steven R Goldberg Journal: Int J Neuropsychopharmacol Date: 2011-09-23 Impact factor: 5.176
Authors: Rodrigo M Leão; Fábio C Cruz; Leandro F Vendruscolo; Giordano de Guglielmo; Marian L Logrip; Cleopatra S Planeta; Bruce T Hope; George F Koob; Olivier George Journal: J Neurosci Date: 2015-04-15 Impact factor: 6.167
Authors: Deniz Bagdas; Clare M Diester; Jason Riley; Moriah Carper; Yasmin Alkhlaif; Dana AlOmari; Hala Alayoubi; Justin L Poklis; M Imad Damaj Journal: Neuropharmacology Date: 2019-06-18 Impact factor: 5.250
Authors: F Scott Hall; Andre Der-Avakian; Thomas J Gould; Athina Markou; Mohammed Shoaib; Jared W Young Journal: Neurosci Biobehav Rev Date: 2015-06-06 Impact factor: 8.989
Authors: Jack E Henningfield; Tracy T Smith; Bethea A Kleykamp; Reginald V Fant; Eric C Donny Journal: Psychopharmacology (Berl) Date: 2016-10-21 Impact factor: 4.530
Authors: Theodore Kazan; Christopher L Robison; Nicole Cova; Victoria M Madore; Sergios Charntikov Journal: Behav Brain Res Date: 2020-02-25 Impact factor: 3.332